Johnson G J, Leis L A, Krumwiede M D, White J G
Hematology/Oncology, Veterans Affairs Medical Center, Minneapolis, MN 55417, USA. mailto:
J Thromb Haemost. 2007 Jul;5(7):1516-29. doi: 10.1111/j.1538-7836.2007.02611.x. Epub 2007 May 7.
Shape change and centralization of granules surrounded by a microtubular coil (internal contraction) are among the earliest morphologic changes observed following platelet activation. Myosin IIA contributes to initiation of platelet shape change, but its role in internal contraction has not been defined.
To define the contribution of myosin IIA to platelet internal contraction.
Aspirin-treated platelets suspended in calcium-free buffer were activated with a low concentration (25 nm) of the thromboxane A(2) analog U46619 which initiated shape change and internal contraction via a Rho kinase pathway. Shape change and internal contraction were assessed by aggregometry and transmission electron microscopy (TEM), and Rho activation and myosin regulatory light chain (MRLC) phosphorylation were studied concurrently.
Low-concentration blebbistatin (10 microm) inhibited internal contraction in the majority of platelets with minimal inhibition of shape change without significant suppression of MRLC phosphorylation. Higher blebbistatin concentrations (25-100 microm) produced concentration-dependent inhibition of aggregation, shape change, Rho activation, and MRLC phosphorylation. These data demonstrate: (i) direct platelet myosin IIA participation in internal contraction; and (ii) inhibition of Rho activation and MRLC phosphorylation by >10 microm blebbistatin.
颗粒被微管盘绕包围(内部收缩)时的形状改变和集中是血小板活化后最早观察到的形态学变化之一。肌球蛋白IIA有助于血小板形状改变的起始,但它在内部收缩中的作用尚未明确。
明确肌球蛋白IIA在血小板内部收缩中的作用。
将悬浮于无钙缓冲液中的阿司匹林处理过的血小板用低浓度(25 nM)的血栓素A2类似物U46619激活,其通过Rho激酶途径引发形状改变和内部收缩。通过凝集测定法和透射电子显微镜(TEM)评估形状改变和内部收缩,并同时研究Rho激活和肌球蛋白调节轻链(MRLC)磷酸化。
低浓度的肌球蛋白磷酸酶抑制剂(10 μM)抑制了大多数血小板的内部收缩,对形状改变的抑制最小,且未显著抑制MRLC磷酸化。较高浓度的肌球蛋白磷酸酶抑制剂(25 - 100 μM)对聚集、形状改变、Rho激活和MRLC磷酸化产生浓度依赖性抑制。这些数据表明:(i)血小板肌球蛋白IIA直接参与内部收缩;(ii)>10 μM的肌球蛋白磷酸酶抑制剂抑制Rho激活和MRLC磷酸化。